{"id":54046,"date":"2023-02-17T14:07:25","date_gmt":"2023-02-17T13:07:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\/"},"modified":"2023-02-17T14:07:25","modified_gmt":"2023-02-17T13:07:25","slug":"atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\/","title":{"rendered":"AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference"},"content":{"rendered":"
\n

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc.<\/a> (Nasdaq: ATRC<\/a>), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Oppenheimer 33rd<\/sup> Annual Healthcare Conference.\n<\/p>\n

<\/a><\/p>\n

\nAtriCure\u2019s management is scheduled to present on Wednesday, March 15, 2023 at 8:00 am Eastern Standard Time. Interested parties may access a live audio webcast of the presentation by visiting the \u201cInvestors\u201d section of the company\u2019s website at https:\/\/ir.atricure.com<\/a>.\n<\/p>\n

\nAbout AtriCure<\/b>\n<\/p>\n

\nAtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure\u2019s Isolator\u00ae<\/sup> Synergy\u2122 Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure\u2019s AtriClip\u00ae<\/sup> Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure\u2019s Hybrid AF\u2122 Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure\u2019s cryoICE cryoSPHERE\u00ae <\/sup>probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com<\/a> or follow us on Twitter @AtriCure<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nAngie Wirick
\n
AtriCure, Inc.
\n
Chief Financial Officer
\n
(513) 755-5334
\n
awirick@atricure.com<\/a>\n<\/p>\n

\nLynn Lewis or Marissa Bych
\n
Gilmartin Group
\n
Investor Relations
\n
lynn@gilmartinir.com<\/a>
marissa@gilmartinir.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Oppenheimer 33rd Annual Healthcare Conference. AtriCure\u2019s management is scheduled to present on Wednesday, March 15, 2023 at 8:00 am … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54046","6":"format-standard","7":"category-industry"},"yoast_head":"\nAtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Oppenheimer 33rd Annual Healthcare Conference. AtriCure\u2019s management is scheduled to present on Wednesday, March 15, 2023 at 8:00 am ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-17T13:07:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230217005005\/en\/649252\/21\/AtriCure_logo_1-color_RBG_Web_010218.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference\",\"datePublished\":\"2023-02-17T13:07:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\\\/\"},\"wordCount\":259,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230217005005\\\/en\\\/649252\\\/21\\\/AtriCure_logo_1-color_RBG_Web_010218.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\\\/\",\"name\":\"AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230217005005\\\/en\\\/649252\\\/21\\\/AtriCure_logo_1-color_RBG_Web_010218.jpg\",\"datePublished\":\"2023-02-17T13:07:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230217005005\\\/en\\\/649252\\\/21\\\/AtriCure_logo_1-color_RBG_Web_010218.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230217005005\\\/en\\\/649252\\\/21\\\/AtriCure_logo_1-color_RBG_Web_010218.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference - Pharma Trend","og_description":"MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Oppenheimer 33rd Annual Healthcare Conference. AtriCure\u2019s management is scheduled to present on Wednesday, March 15, 2023 at 8:00 am ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-17T13:07:25+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230217005005\/en\/649252\/21\/AtriCure_logo_1-color_RBG_Web_010218.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference","datePublished":"2023-02-17T13:07:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\/"},"wordCount":259,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230217005005\/en\/649252\/21\/AtriCure_logo_1-color_RBG_Web_010218.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\/","url":"https:\/\/pharma-trend.com\/en\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\/","name":"AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230217005005\/en\/649252\/21\/AtriCure_logo_1-color_RBG_Web_010218.jpg","datePublished":"2023-02-17T13:07:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230217005005\/en\/649252\/21\/AtriCure_logo_1-color_RBG_Web_010218.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230217005005\/en\/649252\/21\/AtriCure_logo_1-color_RBG_Web_010218.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/atricure-to-participate-in-the-oppenheimer-33rd-annual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54046"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54046\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54046"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54046"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}